This article is more than 5 years old. Information may no longer be current.

B&L will license Plasmin for ophthalmic use

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ROCHESTER, N.Y. — Bausch & Lomb plans to license processed human plasma from Bayer for use in ophthalmology, the company said in a press release.

Plasmin is a product derived from processed human plasma, according to B&L, and “may have potential for use in developing novel therapies for ocular conditions.” The company noted it plans to develop Plasmin technology to treat multiple indications for which vitrectomy surgery is currently used.

According to the release, B&L will make milestone payments to Bayer based on development and further royalties based on product sales. Bayer will continue to develop Plasmin for non-ocular indications.